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results from the published literature, problems arise
where data are incomplete. Thus, more transparent re-
porting of study results are required to aid transferability.
PMT14
IMPROVING THE EVIDENCE BASE OF 
ECONOMIC ANALYSES
Coyle D, Lee KM
Clinical Epidemiology Unit, Loeb Health Research Institute, 
Ottawa Hospital, Ottawa, ON, Canada
OBJECTIVE: To address two specific issues relating to
the conduct of economic analysis based on decision ana-
lytic techniques: the impact on results of different sources
of both effectiveness and resource use data. METHODS:
Sensitivity analysis of erythropoietin use in orthopedic
surgery and alendronate in the treatment of osteoporosis.
Analysis focuses on the effect on the incremental cost-
effectiveness ratio of different sources of treatment effec-
tiveness and resource use. For effectiveness, analysis com-
pared results based on individual clinical trials and meta
analysis. Further analysis compared the results based on
resource use data from the clinical trials and data from
administrative data sets. RESULTS: Results varied greatly
between the different sources of effectiveness and re-
source use data. Based on outcomes from individual clin-
ical trials the cost per QALY gained from alendronate
varied from $27,000 to $104,500. The cost per QALY
gained from a meta analysis of all studies was $35,600.
The cost per life year gained of erythropoietin was more
than ten times greater using actual resource use data in
clinical practice in Ottawa than using trial based data.
CONCLUSIONS: Economic analysis conducted through
decision analytic techniques has been open to criticism
over the ease at which desired results can be obtained. By
adopting standards based on an evidence-based approach
to identifying parameters, such criticisms can be avoided.
Based on the results of this paper we recommend that
meta analysis is the preferred source of outcome data but
routine local data are the best source of resource use data.
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VALIDATION OF FRAMINGHAM REGRESSION 
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Milne RJ1,2
1Health Outcomes Associates Ltd., Auckland, New Zealand; 
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Regression equations from the Framingham Heart Study
(FHS) are used in New Zealand to estimate individual
cardiovascular risk. However, these equations have not
been validated for use in the NZ population. OBJEC-
TIVES: To determine the applicability of FHS regression
equations to the Auckland population, to facilitate eco-
nomic modelling of the management of cardiovascular
risk. METHODS: Population risk profiles for Auckland
were used as inputs to recent FHS equations for CHD
events, stroke and myocardial infarction (MI). Annual
risk was calculated from 5-y risk using a Markov model.
The predictions were compared with 1998-92 MI and
stroke event rates obtained from the MONICA study in
Auckland, and with NZ CHD mortality rates. RE-
SULTS: FHS equations predict the risk of incident MI for
Auckland males age 40–64 within 20%, however they
over-estimate female MI risk by up to 2-fold. The FHS
predicts that CHD event risk stabilises over age 53 for fe-
males although NZ female CHD mortality rates (ICD9
410–414) increase exponentially up to age 80. A FHS
stroke equation fits males 60 years but overestimates
risk for younger men and underestimates stroke risk for
women age 40–74 by 33%. Age-specific relative risk for
females compared with males is consistent across Auck-
land CHD event and mortality data and also NZ CHD
mortality data. CONCLUSIONS: FHS equations with
Auckland risk profile inputs provide a reasonable esti-
mate of population MI risk for Auckland men but not for
women. MI risk for Auckland women can be estimated
from FHS risk for males multiplied by the relative risk
obtained from NZ CHD mortality data. Stroke risk pre-
dicted by the FHS is accurate for NZ men over 60 years
but systematically underestimates risk for NZ women.
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Milne RJ1,2
1Health Outcomes Associates Ltd., Auckland, New Zealand; 
2University of Auckland, Auckland, New Zealand
Commercial and private pilots require an annual risk of
an acute incapacitating cardiovascular (CVD) event
1% to maintain their medical certification. OBJEC-
TIVES: (1) to develop a precise, accurate method for esti-
mation of the risk of an acute, incapacitating cardiovas-
cular event, based on a clinical assessment plus blood
lipids, glucose determination and ECG; (2) to determine
the age at threshold for a range of risk profiles. METH-
ODS: Annual risk of CHD, MI and stroke were deter-
mined from recent Framingham regression equations val-
idated for New Zealand. The risk of an acute incapacitating
CHD event is bounded by MI risk and CHD risk. Age at
threshold was estimated from a weighted combination
of Framingham estimates, assuming that 20% of inci-
dent angina pectoris is incapacitating. RESULTS: A non-
diabetic, non-smoking male with age-specific average
Auckland population lipid profile and systolic blood
pressure will reach the 1% per annum threshold for an
incapacitating cardiovascular event at age 60. Males with
30% lower serum cholesterol and 20 points lower sys-
tolic blood pressure will reach the 1% threshold at age
69. Tobacco smoking reduces the age at threshold by 10
years and diabetes by 7 years for males and 12 years for
females. The age at threshold is 12 years higher for
women versus men with similar modifiable risk factors.
A male with several cardiovascular risk factors could
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reach threshold before age 40. The threshold is 1 to 2
years lower if 50% rather than 20% of new angina is
considered to be incapacitating. CONCLUSION: The
methodology provides a precise, accurate method for es-
timation of CVD risk for commercial and private pilots.
The new method introduces objectivity and a level ‘play-
ing field’ for assessment of pilot cardiovascular risk.
PMT17
DEALING WITH SKEWED DATA: AN EXAMPLE 
USING ASTHMA-RELATED COSTS OF 
MEDICAID CLIENTS
Rascati KL, Smith MJ
The University of Texas, College of Pharmacy, Austin, TX, USA
Inhaled steroid agents are recommended for patients with
chronic asthma. OBJECTIVE: The objective of this study
was to compare asthma-related prescription and medical
costs between a cohort of patients with inhaled steroid
use (experimental) and without inhaled steroid use (con-
trol). METHODS: 99 Medicaid patients with an asthma
diagnosis who received add-in inhaled steroids were
matched to 99 patients with an asthma diagnosis who
used therapies other than inhaled steroids. Data were col-
lected for the 6 months before the addition of an inhaled
steroid (pre-utilization phase); for the 6 months immedi-
ately after the addition (stabilization phase); and for the
6 months after the stabilization phase (post-utilization
phase). RESULTS: Compared to the pre-utilization phase,
prescription costs in the post-utilization phase increased
by an average of $57 per month for the experimental
group, while only increasing by an average of $4 per
month for the control group. Conversely, compared to
the pre-utilization phase, medical costs in the post-utili-
zation phase decreased by an average of $53 per month
for the experimental group and increased by an average
of $14 per month for the control group. These cost data
were not normally distributed. Statistical comparisons
using various methods addressing skewed data were con-
sidered (Mann-Whitney U, log transformation, and boot-
strapping). The advantages and disadvantages of using
each method will be outlined. CONCLUSION: The data
indicate that the addition of inhaled steroids increases
prescription costs while decreasing medical costs. The
level of statistical significance differs depending on the
type of test used.
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BIAS ARISING FROM MISSING DATA IN A 
RETROSPECTIVE STUDY OF THE OUTCOMES 
OF INTRA-ABDOMINAL INFECTIONS
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Steinke D1, Yin D2
1Medicines Monitoring Unit, Ninewells Hospital, Dundee, 
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BACKGROUND: During a retrospective study of intra-
abdominal infections we found that case notes for adult
patients were destroyed or incompletely microfiched if
the patient had no contact with the hospital for six years.
OBJECTIVES: To test the hypothesis that patients with
unobtainable case notes would have higher in-hospital
mortality and that this would bias the study sample.
METHODS: Patients who might have community ac-
quired intra-abdominal infections were identified at three
acute hospitals from Scottish Morbidity Records (SMR)
for 1993 to 1995 by the following ICD9 codes: 567
(peritonitis); 540 (appendicitis); 531–534 (gastric, duode-
nal, peptic or gastrojejunal ulcers with perforation).
Medical records were obtained to validate the diagnosis
and to obtain details of antibiotic therapy and its out-
come. If medical records were unobtainable the date of
death and duration of admission were identified from the
electronic SMR record. RESULTS: A total of 867 cases
were identified. For 339 (39%) of these, case notes were
unobtainable or incomplete. SMR could be used to calcu-
late in hospital mortality and duration of stay for 334
(98%) of patients with unobtainable or incomplete medi-
cal records and 510 (97%) of patients with complete
notes. The proportion of female patients was similar
(51% versus 50%). However, the patients with unob-
tainable or incomplete records were significantly older
(median age 72 versus 53.5; P  0.0001 Wilcoxon test)
and significantly more of them died in hospital (45% ver-
sus 7%; relative risk of death in hospital 6.75; 95% CI
5.08–8.96). Median length of stay (10 days versus 9
days; P  0.27 Wilcoxon test) and total hospital cost
(£2885 versus £2746; P  0.68) were similar in the two
groups. CONCLUSION: Missing data have biased the
study sample by excluding older patients with worse out-
come. Selective destruction of case notes is an important
source of bias in retrospective outcomes studies.
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NON-RANDOMIZED STUDIES COMPARING 
OLANZAPINE AND RISPERIDONE: BASELINE 
SIMILARITIES AND DIFFERENCES
Gibson PJ, Loosbrock DL
Health Outcomes Evaluation Group, Eli Lilly and Company, 
Indianapolis, IN, USA
OBJECTIVE: To review the baseline similarities and dif-
ferences between olanzapine- and risperidone-treated pa-
tients, as described in epidemiologic studies, and recom-
mend a set of potential confounders that should be
addressed in such studies. METHOD: All 24 non-ran-
domized olanzapine-risperidone comparisons cited in
Medline or presented as posters at major psychiatric con-
ferences (APA, ECNP, WPA) through 1999 were in-
cluded. The direction, magnitude, and statistical signifi-
cance of all baseline comparisons of the two treatment
groups were recorded, if available. RESULTS: Across all
use, diagnosis distribution and mean age differed without
consistent direction. Comorbidities, number of different
